- Home
- PSFE vs AUTL Comparison
PSFE vs AUTL Comparison
Compare PSFE & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSFE
- AUTL
- Stock Information
- Founded
- PSFE 1996
- AUTL 2014
- Country
- PSFE United Kingdom
- AUTL United Kingdom
- Employees
- PSFE N/A
- AUTL N/A
- Industry
- PSFE Business Services
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSFE Consumer Discretionary
- AUTL Health Care
- Exchange
- PSFE Nasdaq
- AUTL Nasdaq
- Market Cap
- PSFE 770.1M
- AUTL 625.4M
- IPO Year
- PSFE N/A
- AUTL 2018
- Fundamental
- Price
- PSFE $14.24
- AUTL $1.40
- Analyst Decision
- PSFE Sell
- AUTL Strong Buy
- Analyst Count
- PSFE 4
- AUTL 5
- Target Price
- PSFE $17.38
- AUTL $9.12
- AVG Volume (30 Days)
- PSFE 263.3K
- AUTL 4.4M
- Earning Date
- PSFE 08-12-2025
- AUTL 11-11-2025
- Dividend Yield
- PSFE N/A
- AUTL N/A
- EPS Growth
- PSFE N/A
- AUTL N/A
- EPS
- PSFE N/A
- AUTL N/A
- Revenue
- PSFE $1,676,391,000.00
- AUTL $29,934,000.00
- Revenue This Year
- PSFE $3.18
- AUTL $634.25
- Revenue Next Year
- PSFE $7.05
- AUTL $93.16
- P/E Ratio
- PSFE N/A
- AUTL N/A
- Revenue Growth
- PSFE 0.47
- AUTL 185.17
- 52 Week Low
- PSFE $10.63
- AUTL $1.11
- 52 Week High
- PSFE $26.25
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- PSFE 55.79
- AUTL 29.05
- Support Level
- PSFE $13.86
- AUTL $1.34
- Resistance Level
- PSFE $14.62
- AUTL $1.46
- Average True Range (ATR)
- PSFE 0.46
- AUTL 0.09
- MACD
- PSFE 0.02
- AUTL 0.01
- Stochastic Oscillator
- PSFE 59.16
- AUTL 13.64
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.